Anavex Life Sciences Corp (AVXL)

[Investor2014]

Secondly, and perhaps as importantly, diagnoses shifted dramatically in accordance with the scans, particularly for people without amyloid plaques who had been wrongly diagnosed with AD.

My lingering concern about the strong responders is the possibility of misdiagnosis.

If the genetic biomarkers we are waiting to hear about 25th appears clear cut and when combining that with the mainly high A2-73 blood concentration and mild disease baseline in the strong responders as well as perhaps further coinciding pointers such as A2-73 also maintains the rest of the trial population from declining as rapidly as natural history. Then imo it would go a long way to dispel the idea that the strong responders were simply misdiagnosed.